Oruka Therapeutics (ORKA) News Today $10.71 +0.62 (+6.14%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$10.99 +0.28 (+2.61%) As of 05/2/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Trinity Biotech (NASDAQ:TRIB) vs. Oruka Therapeutics (NASDAQ:ORKA) Critical ContrastMay 5 at 1:49 AM | americanbankingnews.com683 Capital Management LLC Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)683 Capital Management LLC bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 33,875 shares of the company's stock, valued at approximately $May 4 at 7:15 AM | marketbeat.comQ1 EPS Forecast for Oruka Therapeutics Reduced by AnalystOruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for shares of Oruka Therapeutics in a report released on Monday, April 28th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per sharMay 3 at 6:49 AM | marketbeat.comPrice T Rowe Associates Inc. MD Grows Stock Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Price T Rowe Associates Inc. MD increased its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 374.5% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,326,893 shares of the company's stock after buying an additioMay 3 at 4:28 AM | marketbeat.comQ1 EPS Estimates for Oruka Therapeutics Cut by HC WainwrightMay 3 at 1:12 AM | americanbankingnews.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Buy" by BrokeragesOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has received an average rating of "Buy" from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to thMay 3 at 1:11 AM | marketbeat.comWhat is HC Wainwright's Estimate for ORKA Q1 Earnings?Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Oruka Therapeutics in a research note issued to investors on Monday, April 28th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.62) pMay 2 at 8:37 AM | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. cut its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 65.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,200 shares of the company's stock after seMay 2 at 4:46 AM | marketbeat.comQ1 Earnings Estimate for ORKA Issued By HC WainwrightMay 2 at 3:27 AM | americanbankingnews.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of "Buy" from BrokeragesMay 1, 2025 | americanbankingnews.comOruka Therapeutics to Present at Bank of America Securities 2025 Health Care ConferenceApril 29, 2025 | globenewswire.comGeode Capital Management LLC Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Geode Capital Management LLC grew its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 2,348.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 342,418 shares of the company's stock after acquiring an additional 328,434 sApril 28, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Bought by SR One Capital Management LPSR One Capital Management LP lifted its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 14.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 430,330 shares of the company's stock after acquiring aApril 19, 2025 | marketbeat.comOruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on ThursdayOruka Therapeutics (NASDAQ:ORKA) will be releasing earnings before the market opens on Thursday, April 24, Financial Modeling Prep reports.April 18, 2025 | marketbeat.comKennedy Capital Management LLC Buys Shares of 60,494 Oruka Therapeutics, Inc. (NASDAQ:ORKA)Kennedy Capital Management LLC purchased a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 60,494 shares of the company's stocApril 17, 2025 | marketbeat.comFmr LLC Increases Stock Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Fmr LLC grew its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 17.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,512,300 shares of the company's stock after purchasing anApril 16, 2025 | marketbeat.comVanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)Vanguard Group Inc. boosted its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 4,161.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,610,651 shares of the company's stock after acquiring an additional 1,572,853 shares durinApril 16, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Buy" from AnalystsOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has been assigned a consensus rating of "Buy" from the nine analysts that are currently covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to theApril 7, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of "Buy" by AnalystsShares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have received an average recommendation of "Buy" from the nine research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the compaMarch 12, 2025 | marketbeat.comWe're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn RateMarch 8, 2025 | finance.yahoo.comOruka Therapeutics' (ORKA) "Outperform" Rating Reaffirmed at WedbushWedbush reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Friday.March 8, 2025 | marketbeat.comOruka Therapeutics at Risk: Navigating Licensing Challenges and Partner RelianceMarch 8, 2025 | tipranks.comOruka Therapeutics announces preclinical data for ORKA-002March 7, 2025 | markets.businessinsider.comOruka Therapeutics (NASDAQ:ORKA) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPSOruka Therapeutics (NASDAQ:ORKA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.19.March 7, 2025 | marketbeat.comOruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual MeetingMarch 7, 2025 | globenewswire.comOruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 6, 2025 | globenewswire.comOruka Therapeutics sees $1.41 million in stock purchases by Venrock HealthcareMarch 1, 2025 | investing.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires $106,396.06 in StockOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 8,971 shares of the business's stock in a transaction on Wednesday, February 12th. The stock was acquired at an average cost of $11.86 per share, for a total transaction of $106,396.06. Following the transaction, the insider now directly owns 4,044,684 shares in the company, valued at $47,969,952.24. The trade was a 0.22 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.February 28, 2025 | marketbeat.comInsider Buying: Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires 88,794 Shares of StockOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of Oruka Therapeutics stock in a transaction on Friday, February 14th. The stock was bought at an average price of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the acquisition, the insider now directly owns 4,148,428 shares of the company's stock, valued at approximately $47,458,016.32. This trade represents a 2.19 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.February 28, 2025 | marketbeat.comVenrock Healthcare Capital Par Purchases 8,971 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) StockFebruary 28, 2025 | insidertrades.comOruka Therapeutics (ORKA) to Release Earnings on ThursdayOruka Therapeutics (NASDAQ:ORKA) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 22, 2025 | marketbeat.comOruka Therapeutics to Present at Multiple March Investor ConferencesFebruary 19, 2025 | globenewswire.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Buy" from AnalystsShares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have received a consensus rating of "Buy" from the nine brokerages that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating toFebruary 15, 2025 | marketbeat.comStifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)February 10, 2025 | markets.businessinsider.comOruka Therapeutics (NASDAQ:ORKA) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Friday.February 7, 2025 | marketbeat.comWolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform RecommendationFebruary 6, 2025 | msn.comOruka Therapeutics inks exclusive license deal with ParagonFebruary 6, 2025 | msn.comWolfe Research Upgrades Oruka Therapeutics (NASDAQ:ORKA) to Strong-BuyWolfe Research upgraded Oruka Therapeutics to a "strong-buy" rating in a research note on Monday.February 5, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Shares Gap Up - Time to Buy?Oruka Therapeutics (NASDAQ:ORKA) Shares Gap Up - Still a Buy?February 4, 2025 | marketbeat.comWolfe Research Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA)Wolfe Research began coverage on shares of Oruka Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $20.00 price objective for the company.February 4, 2025 | marketbeat.comOruka Therapeutics initiated with an Outperform at Wolfe ResearchFebruary 3, 2025 | markets.businessinsider.comOruka Therapeutics (ORKA) Projected to Post Earnings on ThursdayOruka Therapeutics (NASDAQ:ORKA) will be releasing earnings before the market opens on Thursday, February 6, Financial Modeling Prep reports.January 30, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of "Buy" from AnalystsShares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating onJanuary 21, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month Low - Here's What HappenedOruka Therapeutics (NASDAQ:ORKA) Reaches New 12-Month Low - Time to Sell?January 17, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News SummaryJanuary 16, 2025 | benzinga.comTop 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NVJanuary 14, 2025 | theglobeandmail.comOruka Therapeutics (NASDAQ:ORKA) Trading Down 7.8% - Should You Sell?Oruka Therapeutics (NASDAQ:ORKA) Trading Down 7.8% - Should You Sell?January 13, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Sets New 1-Year Low - What's Next?Oruka Therapeutics (NASDAQ:ORKA) Reaches New 1-Year Low - Time to Sell?January 10, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Down 8% - What's Next?Oruka Therapeutics (NASDAQ:ORKA) Shares Down 8% - Here's What HappenedJanuary 7, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month Low - Here's WhyOruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month Low - Here's WhyDecember 30, 2024 | marketbeat.com Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address ORKA Media Mentions By Week ORKA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORKA News Sentiment▼0.700.73▲Average Medical News Sentiment ORKA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORKA Articles This Week▼173▲ORKA Articles Average Week Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMCR News Today EVO News Today VERA News Today APGE News Today MESO News Today SPRY News Today GPCR News Today OCUL News Today DYN News Today ARDX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORKA) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORKA Stock Free ORKA Stock Alerts